Aclaris醫療 ACRS 深 滬
已收盤 08-15 16:00:00 美东时间
1.87
+0.180
+10.65%
華盛通- 最 高1.895
- 今 開1.71
- 成交量 160.88万股
- 最 低 1.70
- 昨 收 1.69
- 總市值 2.02亿
- 52周最高 5.17
- 市盈率 靜 --
- 換手率 1.49%
- 52周最低 1.05
- 委 比 -3.02%
- 總股本 1.08亿
- 歷史最高 33.88
- 量 比 1.79
- 振 幅 11.54%
- 歷史最低 0.5902
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多TSLP：自免领域崛起的“吸金”明星靶点
（来源：药研网） 前言 2025年上半年，阿斯利康财报显示其呼吸与免疫领域重磅产品Tezspire（TSLP单抗）销售额同比增长高达73%，推动公司整体业绩增长...
08-12 07:55
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aclaris Therapeutics announced positive results from its Phase 2a trial of ITK/JAK3 inhibitor ATI-2138, confirming tolerability and strong efficacy signals in moderate-to-severe atopic dermatitis (AD), validating ITK as a therapeutic target. The company also advanced its anti-TSLP monoclonal antibody Bosakitug into a Phase 2 trial in AD and initiated dosing for its anti-TSLP/IL-4R bispecific antibody ATI-052 in a Phase 1a/1b program. Aclaris repo...
08-07 10:59
盘前异动丨星巴克涨超4%，LendingClub大涨23%，FuboTV涨超9%
7月30日周三，美股三大指数期货在盘前时段小幅走高。今日美国将公布7月ADP就业人数、第二季度实际GDP年化季率初值。美联储FOMC于周四凌晨公布利率决议，鲍威...
07-30 16:24
Aclaris Therapeutics Reveals Top-Line Results from Open-Label Phase 2a Trial of ATI-2138; Primary Endpoint Analysis Confirms Favorable Tolerability Profile Of ATI-2138 Without Certain Risks Associated With Other Agents In The Class; Efficacy Results Show Comparable Outcomes To Approved Therapies With Potential For Improved Tolerability, Supporting Exploration Of Higher Doses In Future Clinical Trials
WAYNE, Pa., July 29, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today
07-30 04:04
Aclaris Therapeutics Announces Positive Top-Line Results from Open-Label Phase 2a Trial of ATI-2138, a Potent and Selective Investigational Inhibitor of ITK and JAK3; Trial Achieves Primary and Key Secondary Endpoints
Aclaris Therapeutics announced positive results from a Phase 2a trial of ATI-2138, an oral covalent inhibitor of ITK and JAK3, in patients with moderate-to-severe atopic dermatitis. The trial demonstrated favorable tolerability with no severe adverse events, comparable efficacy to approved therapies, and strong pharmacodynamic effects validating ITK as a therapeutic target. The company plans to further develop ATI-2138 for alopecia areata and exp...
07-29 20:01
Aclaris Therapeutics Announces Leadership Transition
## 输出 Roland Kolbeck, Ph.D. has been appointed as Chief Scientific Officer of Aclaris Therapeutics, succeeding Joe Monahan, Ph.D., who will remain as Special Scientific Advisor through March 2026. Dr. Kolbeck brings extensive experience in inflammation and antibody development, supporting the company's pipeline of immuno-inflammatory product candidates. Dr. Monahan will continue to contribute during his phased retirement, having built a renowned...
07-28 12:45
Piper Sandler Assumes Aclaris Therapeutics at Overweight, Announces Price Target of $6
Piper Sandler analyst Biren Amin assumes Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight rating and announces Price Target of $6.
07-10 21:16
Aclaris Therapeutics Highlights Clinical Pipeline and Outlook
Aclaris Therapeutics ( ($ACRS) ) has provided an update. On June 30, 2025, Acla...
06-30 23:51
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
Wayne, Pa., June 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has been added to the Russell 3000® and Russell 2000® Indexes following the 2025 Russell US Indexes annual reconstitution, effective June 30, 2025. The Russell US Indexes reconstitution ranks the 4,000 largest US stocks by market capitalization. Russell indexes, widely used by investors, have about $10.6 trillion in assets benchmarked against them. For more in...
06-30 13:31
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
Aclaris Therapeutics, a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, will present at the H.C. Wainwright Virtual Conference on June 30, 2025. The presentation, available live and archived, can be viewed on the company's website for 30 days. Aclaris develops innovative treatments for patients with limited options in immuno-inflammatory diseases.
06-26 20:01
